Drug intelligence / Profile preview

PSMA-0057

Development stage: Unknown
Lead developer: Suzhou Ruihe Pharmaceutical Technology
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

PSMA-0057 is a theranostic radiopharmaceutical agent developed by Suzhou Ruihe Pharmaceutical Technology for the management of prostate cancer. It consists of a ligand with high affinity for Prostate-Specific Membrane Antigen (PSMA), also known as glutamate carboxypeptidase II, which is overexpressed in prostate cancer tissues, especially in metastatic castration-resistant prostate cancer (mCRPC). The agent is designed to be labeled with Gallium-68 ([68Ga]) for diagnostic PET imaging to identify PSMA-positive lesions and with Lutetium-177 ([177Lu]) for targeted radionuclide therapy. The [177Lu]-labeled version delivers therapeutic beta radiation directly to the tumor cells, causing DNA damage and apoptosis, while minimizing exposure to healthy tissues. It is currently being evaluated in Phase I/II clinical trials for patients with PSMA-positive mCRPC.

Other names: Gallium-68 PSMA-0057Gallium68 PSMA-0057Gallium 68 PSMA-0057Lutetium-177 PSMA-0057Lutetium177 PSMA-0057Lutetium 177 PSMA-0057Ga-68 PSMA-0057Ga68 PSMA-0057Ga 68 PSMA-0057Lu-177 PSMA-0057Lu177 PSMA-0057Lu 177 PSMA-0057[68Ga] PSMA-0057[177Lu] PSMA-0057

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on PSMA-0057.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSMA-0057.

Explore the full profile